enGene Therapeutics closed at $1.72 on Nov 4, up 6.17%, 85.9% below its 52-week closing high. Volume of 1.4M shares was 1.71× its 20-day average (above normal).
Split-adjusted performance: -4.4% over one month, -80.6% over six months, -75.1% over one year.
Short interest was 1.5M shares at the Oct 15 settlement, up 7.7% from the prior report (3.4% of float, 1.9 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ENGNenGene Therapeutics | $1.72 | +6.17% | −80.6% | — | — | — | $115.3M | |
| VYGRVoyager Therapeutics | $1.87 | +2.19% | −55.2% | −39.1% | −773.2% | — | $115.2M | Compare |
| ARMPArmata Pharmaceuticals | $3.14 | +1.62% | −65.3% | +15.7% | 2953.8% | — | $116.8M | Compare |
| AVXLAnavex Life Sciences | $1.26 | +5.00% | −62.3% | — | — | — | $116.8M | Compare |
| OTLKOutlook Therapeutics | $0.4621 | +0.46% | +99.4% | −99.4% | −233554.9% | — | $112.5M | Compare |
| BDTXBlack Diamond Therapeutics | $1.90 | +4.97% | −32.6% | — | — | — | $109.2M | Compare |
| LENZLENZ Therapeutics | $3.46 | −1.14% | −64.3% | +9.7% | −581.8% | — | $108.7M | Compare |
| NMRANeumora Therapeutics | $0.5660 | −0.86% | −75.7% | — | — | — | $106.3M | Compare |
| HUMAHumacyte | $0.4500 | +2.16% | −54.2% | +34.9% | −9064.5% | — | $125.0M | Compare |
No recent articles focused on enGene Therapeutics. 1 articles mention it in passing.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
